Reverse Payment Agreement Template for the United States
Generate a bespoke document
What is a Reverse Payment Agreement?
Reverse Payment Agreements emerged from patent disputes under the Hatch-Waxman Act framework in the United States. These agreements are used when a generic manufacturer challenges a brand pharmaceutical company's patent, and the parties decide to settle the dispute. The settlement typically involves the brand company making payments to the generic manufacturer in exchange for delayed market entry. Following the Supreme Court's decision in FTC v. Actavis (2013), these agreements require careful structuring to demonstrate their pro-competitive benefits and avoid antitrust violations.
Frequently Asked Questions
Are reverse payment agreements legally binding under US federal law?
Yes, reverse payment agreements are legally binding contracts under US federal law when properly executed between pharmaceutical companies. However, they must comply with antitrust regulations and FTC oversight to avoid Sherman Act violations. Courts will enforce these agreements unless they contain anticompetitive provisions that harm consumer welfare.
Can the FTC challenge my reverse payment agreement after it's signed?
Yes, the FTC can challenge reverse payment agreements even after execution if they believe the terms violate antitrust laws. Following FTC v. Actavis, the FTC actively scrutinizes these agreements for anticompetitive effects. Companies must file these agreements with the FTC within 30 days and face potential enforcement actions for problematic terms.
How does a reverse payment agreement differ from a standard patent licensing deal?
Reverse payment agreements involve the patent holder paying the alleged infringer to delay market entry, which is the opposite of traditional licensing where the licensee pays royalties. These settlements specifically resolve Hatch-Waxman Act patent disputes between brand and generic drug manufacturers. Unlike regular licenses, they face heightened antitrust scrutiny under the Actavis standard.
How long does it typically take to negotiate a reverse payment settlement?
Reverse payment agreement negotiations typically take 3-12 months depending on the complexity of underlying patent disputes and regulatory issues. The process involves extensive due diligence, antitrust analysis, and coordination with ongoing litigation timelines. Settlement discussions often accelerate as Paragraph IV litigation trial dates approach.
Which federal agencies must review my reverse payment agreement?
The Federal Trade Commission and Department of Justice Antitrust Division both have authority to review reverse payment agreements under US antitrust law. Companies must file copies with the FTC within 30 days of execution. The agencies evaluate whether payment terms create anticompetitive delays that harm consumers through higher drug prices.
Can my reverse payment agreement be invalidated if it lacks proper antitrust analysis?
Yes, courts can invalidate reverse payment agreements that lack adequate antitrust justification under the rule of reason analysis established in FTC v. Actavis. Agreements with large unexplained payments and significant entry delays face heightened scrutiny. Companies must demonstrate that any payments serve legitimate purposes beyond delaying generic competition.
What mistakes commonly invalidate reverse payment agreements in federal court?
Common fatal mistakes include excessive payment amounts without business justification, blanket restrictions on all generic competition, and failure to limit payment scope to legitimate litigation costs. Courts also scrutinize agreements that delay entry beyond the patent's natural expiration or include market allocation provisions. Proper documentation of payment rationale is essential for antitrust defense.
About the Reverse Payment Agreement
When you're involved in pharmaceutical patent litigation between a brand drug company and generic manufacturer, you may need a reverse payment agreement to settle the dispute. These complex legal instruments have become essential tools in the pharmaceutical industry for resolving patent challenges while maintaining regulatory compliance under strict federal antitrust scrutiny.
When do you need this document?
You'll need a reverse payment agreement when facing Paragraph IV patent challenges under the Hatch-Waxman Act, where a generic manufacturer has filed an Abbreviated New Drug Application (ANDA) certifying that your patents are invalid or will not be infringed. These agreements become necessary when litigation costs and uncertain outcomes make settlement more attractive than continued court battles. You may also require this document when seeking to manage generic entry timing while avoiding the risk of antitrust violations that could result in treble damages and criminal penalties. Additionally, these agreements are essential when you need to satisfy FDA approval timelines while maintaining market exclusivity periods.
Key legal considerations
Your reverse payment agreement must carefully balance settlement benefits against antitrust risks identified in FTC v. Actavis. The Supreme Court established that these agreements face "rule of reason" analysis, meaning you must demonstrate that any payments serve legitimate business purposes beyond delaying generic competition. You need to ensure that payment amounts don't exceed avoided litigation costs and that any restrictions on generic entry are reasonably related to the scope and strength of your patents. The agreement must include robust justifications for payment structures, whether they involve cash, licensing deals, or other value transfers. You should also address potential FTC challenges by documenting the pro-competitive benefits, such as enabling earlier generic entry than successful patent litigation would allow.
Legal requirements in United States
Under federal law, your reverse payment agreement must comply with FTC reporting requirements mandated by the Medicare Prescription Drug, Improvement, and Modernization Act. You must file detailed reports with the FTC and DOJ within 30 days of execution, disclosing all terms including payment amounts, restricted activities, and market entry dates. The agreement must satisfy Sherman Antitrust Act provisions by avoiding unreasonable restraints on trade and ensuring that any market division reflects legitimate patent scope. You need to structure payment terms to withstand Clayton Act scrutiny, particularly regarding potential monopolization effects. Additionally, your agreement must align with FDA regulations governing ANDA approvals and comply with any court-ordered timelines from underlying patent litigation. Consider including provisions for regulatory approval contingencies and ensure that your settlement terms don't conflict with existing consent decrees or FTC enforcement actions.
GOVERNING LAW
Applicable law
This Reverse Payment Agreement is drafted to comply with United States law. Key legislation includes:
Explore 208,390+ legal templates
Explore 208,390+ legal templates
Genie's Security Promise
Genie is the safest place to draft. Here's how we prioritise your privacy and security.
Your data is private:
We do not train on your data; Genie's AI improves independently
All data stored on Genie is private to your organisation
Your documents are protected:
Your documents are protected by ultra-secure 256-bit encryption
We are ISO27001 certified, so your data is secure
Organizational security:
You retain IP ownership of your documents and their information
You have full control over your data and who gets to see it